ALB and neoplasm: So far, improvements in blood retention and tumor uptake have been reported using the albumin-binding variant [177Lu]Lu‐DOTA‐EB-TATE, which is currently evaluated in clinical phase I and II trials (NCT05475210, NCT03478358) 15, 16.